Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sporax is an antibiotic brand manufactured and distributed by Rax Health Care, containing the active ingredient cephalexin. As a first-generation cephalosporin, it functions by inhibiting bacterial cell wall synthesis through the binding and inactivation of penicillin-binding proteins (PBPs), which are essential for the cross-linking of peptidoglycan layers. This disruption leads to bacterial cell lysis and death. Sporax is indicated for the treatment of various susceptible bacterial infections, including those affecting the respiratory tract, middle ear (otitis media), skin and soft tissues, bones, and the urinary tract. It is available in multiple formulations, including oral capsules and a dry syrup (which is reconstituted into an oral suspension), as well as liquid drops for oral or topical use depending on the specific product form.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Sporax.